As such, early promising synergistic effects of targeting RAS and FAK have been observed in several cell lines and patient-derived xenograft models [83], with several clinical trials taking place currently [84] (see Outstanding questions).Outstanding questionsHow do RAS-driven changes in the mechanical properties of individual cells measured in vitro manifest in vivo within a tumour microenvironment? Here, PTK2 is linked to neoplasm.